Literature DB >> 20952197

A single, low, oral dose of a 5-carbon-linked trioxane dimer orthoester plus mefloquine cures malaria-infected mice.

Deuk Kyu Moon1, Abhai Tripathi, David Sullivan, Maxime A Siegler, Sean Parkin, Gary H Posner.   

Abstract

Four 5-carbon-linked trioxane dimer orthoesters (6a-6d) have been prepared in 4 or 5 chemical steps from the natural trioxane artemisinin (1). When administered orally to malaria-infected mice using a single dose of only 6 mg/kg body weight along with 18 mg/kg of mefloquine hydrochloride, trioxane dimer orthoester sulfone 6d completely and safely cured the mice; after 30 days, the cured mice showed no detectable parasitemia, gained at least as much weight as the control mice (no infection), and behaved normally.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952197      PMCID: PMC3037442          DOI: 10.1016/j.bmcl.2010.09.123

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  21 in total

Review 1.  A medicinal chemistry perspective on artemisinin and related endoperoxides.

Authors:  Paul M O'Neill; Gary H Posner
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

Review 2.  Artemisinin-based combinations.

Authors:  Elizabeth A Ashley; Nicholas J White
Journal:  Curr Opin Infect Dis       Date:  2005-12       Impact factor: 4.915

Review 3.  Fluoroartemisinins: metabolically more stable antimalarial artemisinin derivatives.

Authors:  Jean-Pierre Bégué; Danièle Bonnet-Delpon
Journal:  ChemMedChem       Date:  2007-05       Impact factor: 3.466

4.  Stability of acetal and non acetal-type analogs of artemisinin in simulated stomach acid.

Authors:  M Jung; S Lee
Journal:  Bioorg Med Chem Lett       Date:  1998-05-05       Impact factor: 2.823

5.  Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy.

Authors:  Gary H Posner; Ik-Hyeon Paik; Surojit Sur; Andrew J McRiner; Kristina Borstnik; Suji Xie; Theresa A Shapiro
Journal:  J Med Chem       Date:  2003-03-13       Impact factor: 7.446

Review 6.  Synthetic peroxides as antimalarials.

Authors:  Yuanqing Tang; Yuxiang Dong; Jonathan L Vennerstrom
Journal:  Med Res Rev       Date:  2004-07       Impact factor: 12.944

Review 7.  Efficacy and safety of dihydroartemisinin-piperaquine.

Authors:  H Y Myint; E A Ashley; N P J Day; F Nosten; N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  2007-07-19       Impact factor: 2.184

8.  Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate.

Authors:  Fernando de Pilla Varotti; Ana Cristina C Botelho; Anderson Assunção Andrade; Renata C de Paula; Elaine M S Fagundes; Alessandra Valverde; Lúcia M U Mayer; Jorge Souza Mendonça; Marcus V N de Souza; Núbia Boechat; Antoniana Ursine Krettli
Journal:  Antimicrob Agents Chemother       Date:  2008-08-18       Impact factor: 5.191

Review 9.  Qinghaosu (artemisinin): an antimalarial drug from China.

Authors:  D L Klayman
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

10.  The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Adama Gansané; Amidou Diarra; Amidou Ouédraogo; Amadou T Konaté; Jean René Kiechel; Caroline C Morgan; Piero L Olliaro; Walter R J Taylor
Journal:  Malar J       Date:  2009-03-16       Impact factor: 2.979

View more
  9 in total

1.  Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.

Authors:  Rachel D Slack; Bryan T Mott; Lauren E Woodard; Abhai Tripathi; Abhai Triphati; David Sullivan; Elizabeth Nenortas; Sonya C T Girdwood; Theresa A Shapiro; Gary H Posner
Journal:  J Med Chem       Date:  2011-12-15       Impact factor: 7.446

2.  The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether.

Authors:  Ryan C Conyers; Jennifer R Mazzone; Maxime A Siegler; Abhai K Tripathi; David J Sullivan; Bryan T Mott; Gary H Posner
Journal:  Bioorg Med Chem Lett       Date:  2014-01-30       Impact factor: 2.823

3.  Malaria-infected mice live until at least day 30 after a new artemisinin-derived thioacetal thiocarbonate combined with mefloquine are administered together in a single, low, oral dose.

Authors:  Alexander M Jacobine; Jennifer R Mazzone; Rachel D Slack; Abhai K Tripathi; David J Sullivan; Gary H Posner
Journal:  J Med Chem       Date:  2012-08-27       Impact factor: 7.446

4.  Antimalarial Natural Products.

Authors:  David G I Kingston; Maria Belen Cassera
Journal:  Prog Chem Org Nat Prod       Date:  2022

5.  Antimalarial chemotherapy: artemisinin-derived dimer carbonates and thiocarbonates.

Authors:  Jennifer R Mazzone; Ryan C Conyers; Abhai K Tripathi; David J Sullivan; Gary H Posner
Journal:  Bioorg Med Chem Lett       Date:  2014-04-16       Impact factor: 2.823

Review 6.  Recent advances in malaria drug discovery.

Authors:  Marco A Biamonte; Jutta Wanner; Karine G Le Roch
Journal:  Bioorg Med Chem Lett       Date:  2013-03-27       Impact factor: 2.823

7.  Synthesis and antimalarial efficacy of two-carbon-linked, artemisinin-derived trioxane dimers in combination with known antimalarial drugs.

Authors:  Bryan T Mott; Abhai Tripathi; Maxime A Siegler; Cathy D Moore; David J Sullivan; Gary H Posner
Journal:  J Med Chem       Date:  2013-03-07       Impact factor: 7.446

8.  Antimalarial efficacy of hydroxyethylapoquinine (SN-119) and its derivatives.

Authors:  Natalie G Sanders; David J Meyers; David J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

9.  An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities.

Authors:  Ran He; Bryan T Mott; Andrew S Rosenthal; Douglas T Genna; Gary H Posner; Ravit Arav-Boger
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.